SCHEMBL5547376

SCHEMBL5547376

C[C@](O)(COC(=O)N1CC=C(c2ccc(F)cc2)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.41
GRM1 Q13255 5/20 0.41
PARP1 P09874 3/20 0.38
ENPP2 Q13822 1/20 0.37
SOS1 Q07889 1/20 0.37
KIT P10721 2/20 0.36
PARP2 Q9UGN5 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MAPK1 P28482 1/20 0.34
TLR7 Q9NYK1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547380 1.00 GRM5 (0.41) GRM5GRM1PARP1ENPP2SOS1
SCHEMBL5541962 0.94 ENPP2 (0.38) GRM5GRM1ENPP2KITMAPT
SCHEMBL5541952 0.94 ENPP2 (0.38) GRM5GRM1ENPP2KITMAPT
SCHEMBL5536346 0.92 TRPV1 (0.38)
SCHEMBL5536356 0.92 TRPV1 (0.38)
SCHEMBL5542334 0.92 SIGMAR1 (0.33) GRM5GRM1ENPP2TLR7SIGMAR1
SCHEMBL5542342 0.92 SIGMAR1 (0.33) GRM5GRM1ENPP2TLR7SIGMAR1
SCHEMBL5544841 0.91 GRM1 (0.35) GRM5GRM1ENPP2ALDH1A1HPGD
SCHEMBL5544836 0.91 GRM1 (0.35) GRM5GRM1ENPP2ALDH1A1HPGD
SCHEMBL5537384 0.91 TRPV1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GRM5 897/4885GRM1 169/4885PARP1 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.